Intrauterine infusion of clinically graded human umbilical cord-derived mesenchymal stem cells for the treatment of poor healing after uterine injury: a phase I clinical trial

Table 1 Patients demographic and injection dosing

Study ID	Age	Disease duration (years)	Weight (kg)	Height (cm)	Diagnosis	Clinical symptoms	The dose of hUC-MSCs per IU injection
Study ID	Age	Disease duration (years)	Weight (kg)	Height (cm)	Diagnosis	Clinical symptoms	1st dose	2nd dose
01	30	6	55	163	CSD	Prolonged Menstrual period	1.85 × 10⁷	2.14 × 10⁷
02	38	4	51	156	IUA	Hypomenorrhea	1.89 × 10⁷	2.08 × 10⁷
03	30	2	50	163	IUA	Hypomenorrhea	1.90 × 10⁷	1.94 × 10⁷
04	29	4	57	158	IUA	Amenorrhea	1.84 × 10⁷	1.90 × 10⁷
05	38	2	54	156	IUA	Hypomenorrhea	2.04 × 10⁷	2.18 × 10⁷
06	34	1	58	167	CSD	Prolonged Menstrual period	1.86 × 10⁷	2.12 × 10⁷
07	34	6	49	158	IUA	Hypomenorrhea	2.08 × 10⁷	1.92 × 10⁷
08	40	1	54	165	CSD	Prolonged Menstrual period	2.02 × 10⁷	1.91 × 10⁷
09	33	2	52	152	CSD	Prolonged Menstrual period	2.02 × 10⁷	2.34 × 10⁷
10	33	3	45	160	IUA	Amenorrhea	2.16 × 10⁷	2.08 × 10⁷

CSD cesarean scar diverticulum, IUA intrauterine adhesion, hUC-MSCs human umbilical cord mesenchymal stem cells

ISSN: 1757-6512